HanchorBio Secures Approval for TWSE Innovation Board Listing, Aiming for Global Expansion HanchorBio has announced its upcoming listing on the TWSE Innovation Board, aiming to boost clinical development and strengthen institutional partnerships.

HanchorBio Secures Approval for TWSE Innovation Board Listing, Aiming for Global Expansion #Taiwan #Taipei #biotech_company #HanchorBio #TWSE_Innovation_Board

HanchorBio's HCB101 Receives Significant FDA Orphan Drug Designation for Gastric Cancer Treatment HanchorBio has achieved a major milestone with the FDA granting Orphan Drug Designation for HCB101 in treating gastric cancer, highlighting its unmet medical need in this area.

HanchorBio's HCB101 Receives Significant FDA Orphan Drug Designation for Gastric Cancer Treatment #Taipei #United_States #HanchorBio #HCB101 #GastricCancer

HanchorBio Expands Global Presence with Impactful Presentations at Key Oncology Conferences in Early 2026 HanchorBio, a leading biotech firm, showcases significant advancements in immunotherapy at various prestigious oncology events in early 2026.

HanchorBio Expands Global Presence with Impactful Presentations at Key Oncology Conferences in Early 2026 #Taiwan #Taipei #oncology #Immunotherapy #HanchorBio

HanchorBio and WuXi Biologics Forge Strategic Alliance to Propel Next-Gen Biologics Development HanchorBio and WuXi Biologics have signed a collaboration agreement to enhance the development of advanced fusion proteins aimed at revolutionizing cancer and autoimmune treatments.

HanchorBio and WuXi Biologics Forge Strategic Alliance to Propel Next-Gen Biologics Development #None #WuXi_Biologics #HanchorBio #fusion_proteins

HanchorBio's HCB101 Receives Prestigious Presentation Spot at ESMO Immuno-Oncology Congress 2025 HanchorBio's innovative therapy, HCB101, is set to be featured at the ESMO Immuno-Oncology Congress 2025, showcasing advancements in treating aggressive cancers.

HanchorBio's HCB101 Receives Prestigious Presentation Spot at ESMO Immuno-Oncology Congress 2025 #London #United_Kingdom #Immuno-Oncology #HanchorBio #HCB101

HanchorBio Unveils Promising Data for HCB101 Monotherapy in Non-Hodgkin Lymphoma at ASH 2025 HanchorBio has presented significant Phase 1 data for HCB101, showcasing its safe and effective monotherapy in treating relapsed or refractory non-Hodgkin lymphoma at ASH 2025.

HanchorBio Unveils Promising Data for HCB101 Monotherapy in Non-Hodgkin Lymphoma at ASH 2025 #USA #Orlando #HanchorBio #HCB101 #Non-Hodgkin_Lymphoma

HanchorBio Unveils Promising Results at Immunotherapy Meeting for Advanced Cancer Treatment with HCB101 At the Society for Immunotherapy of Cancer meeting, HanchorBio presented groundbreaking data on HCB101, showcasing its potential in treating advanced cancers safely and effectively.

HanchorBio Unveils Promising Results at Immunotherapy Meeting for Advanced Cancer Treatment with HCB101 #Taiwan #Taipei #HanchorBio #HCB101 #CancerTreatment

HanchorBio Unveils Promising Preclinical Data on Innovative Fusion Protein HCB301 at SITC 2025 At the SITC 2025 conference, HanchorBio revealed groundbreaking data on HCB301, showcasing its potential in cancer immunotherapy through multi-targeting.

HanchorBio Unveils Promising Preclinical Data on Innovative Fusion Protein HCB301 at SITC 2025 #USA #Maryland #Immunotherapy #HanchorBio #HCB301

Promising Phase 1 Clinical Results of HCB101 Unveiled at FACO 2025 HanchorBio presents promising early clinical findings for their HCB101 therapy at FACO 2025, showcasing safety and potential effectiveness against tumors.

Promising Phase 1 Clinical Results of HCB101 Unveiled at FACO 2025 #China #Shanghai #cancer_therapy #HanchorBio #HCB101

HanchorBio’s Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology Prestigious peer-review validates HCB101’s differentiated mechanism and translational strength. Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono) TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a […] The post HanchorBio’s Novel CD47-SIRPα Therapeutic HCB101 first appeared on AsiaNewsToday.

HanchorBio’s Novel CD47-SIRPα Therapeutic HCB101 #HanchorBio #HCB101 #CD47SIRPalpha #CancerResearch #Oncology

HanchorBio's Promising HCB101 Therapy Receives Publication in Top Hematology Journal HanchorBio reports that their innovative therapy HCB101 has been accepted for publication in a prestigious journal, highlighting its unique efficacy and safety.

HanchorBio's Promising HCB101 Therapy Receives Publication in Top Hematology Journal #Taiwan #Taipei #HanchorBio #HCB101 #CD47-SIRPα

HanchorBio's HCB101 Fusion Protein Gains US Patent: A Game Changer in Cancer Therapy HanchorBio has received a US patent for HCB101, an innovative SIRPα/CD47 fusion protein, enhancing its potential in immuno-oncology therapies.

HanchorBio's HCB101 Fusion Protein Gains US Patent: A Game Changer in Cancer Therapy #Taipei #United_States #Immuno-Oncology #HanchorBio #HCB101

HanchorBio Accelerates Oncology Innovations with HCB101 and HCB301 Presentation Insights HanchorBio showcases their innovative immunotherapies HCB101 and HCB301, which will be presented at major oncology meetings in late 2025, demonstrating promising advancements in cancer treatment.

HanchorBio Accelerates Oncology Innovations with HCB101 and HCB301 Presentation Insights #Taiwan #Taipei #HanchorBio #HCB101 #HCB301

HanchorBio's HCB301 Abstract Accepted for Presentation at SITC 2025 Annual Meeting HanchorBio has announced that its abstract on HCB301, an innovative cancer treatment, has been accepted for a poster presentation at the SITC 2025 Annual Meeting in Maryland.

HanchorBio's HCB301 Abstract Accepted for Presentation at SITC 2025 Annual Meeting #USA #Cancer_Treatment #National_Harbor #HanchorBio #HCB301

HanchorBio's Listing on TPEx Enhances the Reach of HCB101 Immunotherapy HanchorBio Inc. is now listed on Taiwan's TPEx, enhancing its global presence. The company aims to revolutionize cancer treatment with its innovative HCB101 immunotherapy.

HanchorBio's Listing on TPEx Enhances the Reach of HCB101 Immunotherapy #Taiwan #Taipei #HanchorBio #HCB101 #Taipei_Exchange

HanchorBio and Henlius Forge Strategic Licensing Agreement to Enhance Global Immuno-Oncology Development HanchorBio has announced a significant licensing agreement with Henlius for HCB101, aiming to boost its footprint in immuno-oncology across multiple regions, including Greater China and MENA.

HanchorBio and Henlius Forge Strategic Licensing Agreement to Enhance Global Immuno-Oncology Development #Taiwan #Taipei #Henlius #HanchorBio #HCB101

HanchorBio Reveals Groundbreaking Interim Data on HCB101 Immunotherapy at ASCO 2025 HanchorBio Inc. presents promising interim results of HCB101, a novel checkpoint inhibitor immunotherapy, at ASCO 2025, showcasing its strong safety profile and early efficacy against cancer.

HanchorBio Reveals Groundbreaking Interim Data on HCB101 Immunotherapy at ASCO 2025 #United_States #Chicago #Immunotherapy #HanchorBio #HCB101